Postprandial HypotensionGastroflowNCT07381816
GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension
A study testing MRI + GIPR antagonist (Tool), MRI + hangrip and Saline and oral glucose in people with Postprandial Hypotension and Healthy, run by University of Copenhagen at 1 site in Denmark.
Trial summary
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with postprandial hypotension. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Postprandial Hypotension, Healthy, Blood Flow
- What is being tested?
- MRI + GIPR antagonist (Tool), MRI + hangrip and Saline and oral glucose
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteDenmark
- Study dates
- 15 Sep 2025to 1 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Postprandial hypotension
- Symptoms of postprandial hypotension
- Matched by age, gender and BMI
Who cannot join
- Treatment with drugs that cannot be paused for 12 hours
- Metallic implants that does not tolerate MRI
- Any other disease or dysfunction that may disturb blood flow to the gut
- Intake of more than 14 units of alcohol per week or abuse of drugs
- Blood vessels that are not feasible for measuring flow in the MRI scanner
- Low blood percent
Show all 20Show fewer
- Decreased kidney function
- Decreased liver function
- Claustrophobia
- For the healthy group
- Postprandial hypotension
- Metallic implants that does not tolerate MRI
- Intake of more than 14 units of alcohol per week or abuse of drugs
- Blood vessels that are not feasible for measuring flow in the MRI scanner
- Low blood percent
- Decreased kidney function
- Decreased liver function
- Claustrophobia
- Autonomic dysfunction or other disease that cause changes in blood pressure during or after a meal
- Intake of pharmaceutical products that influence the blood pressure
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with postprandial hypotension.
Read the detailed description
Each participant will attend three independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2). Furthermore one day will be with handgrip exercise, without an infusion. Therefore the first two days are in randomized order.
MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines and pancreas.
- Conditions
- Postprandial Hypotension, Healthy, Blood Flow
- Being tested
- MRI + GIPR antagonist (Tool), MRI + hangrip, Saline and oral glucose
- Keywords
- Physiology, GIP, Blood flow, Postprandial hypotension, Splanchnic blood flow, Mesenteric blood flow
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI + GIPR antagonist (Tool)Other
GIP(3-30)NH2 infusion, oral glucose during MRI scans
MRI + hangripOther
Hangrip exercises, oral glucose during MRI scans
Saline and oral glucoseOther
Saline infusion oral glucose during MRI scans
| Study group | Role | What they receive |
|---|---|---|
| Postprandial hypotension group | Experimental | MRI scans of PPH patients. 3 interventions Receives: Other: MRI + GIPR antagonist (Tool); Other: MRI + hangrip; Other: Saline and oral glucose |
| Healthy matched controls | Placebo comparator | MRI scans of healthy controls. Crossover design three interventions. Receives: Other: MRI + GIPR antagonist (Tool); Other: MRI + hangrip; Other: Saline and oral glucose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood flow
Redistribution of splanchnic blood flow in the vessel mesenteric superior artery. Measured with functional MRI in ml/min
Measured: 145 minutes
Secondary outcomes (2)
Blood flow
Blood flow in vena portae
Measured: 145 minutes
Blood flow
Blood flow in trunks coeliacus
Measured: 145 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2026
- Study start15 Sep 2025
- Primary completion1 Dec 2026 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postprandial HypotensionStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Single blind, placebo controlled, randomized, crossover study
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- Copenhagen University Hospital, Rigshospitalet
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07381816
- Sponsor's protocol ID
- H-25007666
- Other IDs
- NNF23OC0082437
- Acronym
- Gastroflow
- Status last verified
- Sep 2025
- First submitted
- 3 Sep 2025
- Last updated
- 2 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension
- ClinicalTrials.gov ID
- NCT07381816
- Acronym / sponsor ID
- Gastroflow / H-25007666
- Conditions
- Postprandial Hypotension, Healthy, Blood Flow
- Keywords
- Physiology, GIP, Blood flow, Postprandial hypotension, Splanchnic blood flow, Mesenteric blood flow
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Collaborators
- Copenhagen University Hospital, Rigshospitalet
- Study start
- 15 Sep 2025 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 2 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with postprandial hypotension.
Detailed description
Each participant will attend three independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2). Furthermore one day will be with handgrip exercise, without an infusion. Therefore the first two days are in randomized order.
MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines and pancreas.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Single blind, placebo controlled, randomized, crossover study
| Arm | Type | Receives |
|---|---|---|
| Postprandial hypotension group | Experimental | Other: MRI + GIPR antagonist (Tool), Other: MRI + hangrip, Other: Saline and oral glucoseMRI scans of PPH patients. 3 interventions |
| Healthy matched controls | Placebo comparator | Other: MRI + GIPR antagonist (Tool), Other: MRI + hangrip, Other: Saline and oral glucoseMRI scans of healthy controls. Crossover design three interventions. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Postprandial hypotension
- Symptoms of postprandial hypotension
- Matched by age, gender and BMI
Key exclusion criteria (20 listed)
- Treatment with drugs that cannot be paused for 12 hours
- Metallic implants that does not tolerate MRI
- Any other disease or dysfunction that may disturb blood flow to the gut
- Intake of more than 14 units of alcohol per week or abuse of drugs
- Blood vessels that are not feasible for measuring flow in the MRI scanner
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI + GIPR antagonist (Tool)GIP(3-30)NH2 infusion, oral glucose during MRI scans | Other | Healthy matched controls, Postprandial hypotension group |
| MRI + hangripHangrip exercises, oral glucose during MRI scans | Other | Healthy matched controls, Postprandial hypotension group |
| Saline and oral glucoseSaline infusion oral glucose during MRI scans | Other | Healthy matched controls, Postprandial hypotension group |
Primary outcome
Blood flow
Time frame: 145 minutes
Redistribution of splanchnic blood flow in the vessel mesenteric superior artery. Measured with functional MRI in ml/min
2 secondary outcomes
Blood flow
Time frame: 145 minutes
Blood flow
Time frame: 145 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2026.
Related trials for Postprandial Hypotension
Not yet recruitingObservational study
Postprandial Hypotension, Frailty and Post-Induction Hypotension in Older Patients Undergoing Noncardiac Surgery
Post-induction Hypotension (PIH), Postprandial Hypotension
Recruiting
Diet and Exercise Solutions to Postprandial Hypotension
Spinal Cord Injuries
Not yet recruitingObservational study
Orthostatic And Postprandial Hypotension In Hospitalized Older Adults (HOPE65)
Orthostatic Hypotension, Postprandial Hypotension
Enrolling by invitation
The Involvement of the Gut Hormone GIP in the Pathophysiology of Post Prandial Hypotension
PostPrandial Hypotension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRI + GIPR antagonist (Tool), MRI + hangrip and Saline and oral glucose in people with Postprandial Hypotension and Healthy, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 2 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood flow (time frame: 145 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2026.